可溶性尿激酶型纤溶酶原激活物受体（suPAR）在脓毒症中的研究进展  

Research progress on soluble urokinase plasminogen activator receptor in sepsis

作　　者：刘宣(综述)[1] 王海嵘(综述)[1] 潘曙明(审校)[1] 

机构地区：[1]上海交通大学医学院附属新华医院急救中心,上海200092

出　　处：《中国急救医学》2012年第9期845-848,共4页Chinese Journal of Critical Care Medicine

摘　　要：可溶性尿激酶型纤溶酶原激活物受体 （soluble urokinase plasminogen activatorreceptor, suPAR）是表达于多种免疫活化细胞表面的尿激酶型纤溶酶原激活物受体（ urokinase plasminogen activator receptor, uPAR）的可溶形式。在炎症或感染的过程中，血清中suPAR的水平可反映机体免疫系统的激活程度。目前，已有多项研究揭示，suPAR作为一种新型的炎症标志物，在脓毒症的早期诊断、预后评估、严重程度分级以及指导治疗等方面具有一定的价值。鉴于该标志物预测脓毒症患者预后情况的准确性，临床医生也许可以利用suPAR对脓毒症患者进行早期的危险分级，从而为今后开展个体化的治疗提供依据。Soluble urokinase plasminogen activator receptor （suPAR） is the soluble form of the urokinase plasminogen activator receptor （ uPAR）, which is expressed on variously immunological active cell types. Serum concentrations of suPAR are suggested to mirror the degree of the activation of the immune system in the circumstances of inflammation or infection. Currently, a number of researches have found that suPAR, as a novel inflammatory marker, is of some value to early diagnosis, prognostic prediction, the assessment of disease severity and therapeutic guidance in sepsis. Considering its superior predictive accuracy for survival, suPAR may help clinicians stratify the patients with different prognosis in the early phase of sepsis in order to target therapeutic interventions in the days to come.

关 键 词：可溶性尿激酶型纤溶酶原激活物受体(suPAR) 脓毒症 预后评估 

分 类 号：R735[医药卫生—肿瘤]